Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1112759

1.

Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.

Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P.

Int J Radiat Oncol Biol Phys. 2018 Oct 12. pii: S0360-3016(18)33856-2. doi: 10.1016/j.ijrobp.2018.10.005. [Epub ahead of print]

PMID:
30321689
2.

The Natural Course of Myxopapillary Ependymoma : An Unusual Case Report and Review of The Literature.

Pusat S, Cem Erbaş Y, Göçmen S, Kocaoğlu M, Erdoğan E.

World Neurosurg. 2018 Oct 12. pii: S1878-8750(18)32321-0. doi: 10.1016/j.wneu.2018.10.028. [Epub ahead of print]

PMID:
30321682
3.

Observations from Social Media Regarding the Symptomatology of Adult Hydrocephalus Patients.

Agarwal N, Lariviere WR, Henry LC, Faramand A, Koschnitzky JE, Friedlander RM.

World Neurosurg. 2018 Oct 12. pii: S1878-8750(18)32320-9. doi: 10.1016/j.wneu.2018.10.027. [Epub ahead of print]

PMID:
30321673
4.

The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.

Etheridge T, Liou JI, Downs TM, Abel EJ, Jarrard DF, Richards KA.

J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.10.005. [Epub ahead of print]

PMID:
30321553
5.

Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities study cohort.

Palta P, Sharrett AR, Deal JA, Evenson KR, Gabriel KP, Folsom AR, Gross AL, Windham BG, Knopman D, Mosley TH, Heiss G.

Alzheimers Dement. 2018 Oct 12. pii: S1552-5260(18)33517-9. doi: 10.1016/j.jalz.2018.08.008. [Epub ahead of print]

PMID:
30321503
6.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [Epub ahead of print]

PMID:
30321406
7.

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

Madan RA, Gulley JL.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy145. [Epub ahead of print] No abstract available.

PMID:
30321404
8.

Body weight and physical activity of adolescents in Malaysia.

Tan AKG, Yen ST, Fang X, Chiang FS.

Int Health. 2018 Oct 15. doi: 10.1093/inthealth/ihy072. [Epub ahead of print]

PMID:
30321364
9.

Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.

Leighton X, Bera A, Eidelman O, Bubendorf L, Zellweger T, Banerjee J, Gelmann EP, Pollard HB, Srivastava M.

PLoS One. 2018 Oct 15;13(10):e0205837. doi: 10.1371/journal.pone.0205837. eCollection 2018.

10.

Cross-sectional white matter microstructure differences in age and trait mindfulness.

Boekel W, Hsieh S.

PLoS One. 2018 Oct 15;13(10):e0205718. doi: 10.1371/journal.pone.0205718. eCollection 2018.

11.

[New strategies in specific care for benign prostatic hypertrophy in older men].

Albisinni S, Legrand F, Roumeguère T.

Rev Med Brux. 2018;39(4):372-378. French.

PMID:
30321003
12.

Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells.

Rencüzoğullari Ö, Arısan ED, Obakan Yerlikaya P, Çoker Gürkan A, Keskin B, Palavan Ünsal N.

J Cell Biochem. 2018 Oct 15. doi: 10.1002/jcb.27840. [Epub ahead of print]

PMID:
30320903
13.

Novel Mapping Method for the Intraoperative Neurophysiologic Monitoring of Sexual Function During Prostate Surgery.

Martín-Palomeque G, Cabañes-Martínez L, de Blas Beorlegui G, Moreno Galera MDM, López JR, Burgos FJ, Regidor Bailly-Baillière I.

J Clin Neurophysiol. 2018 Oct 10. doi: 10.1097/WNP.0000000000000506. [Epub ahead of print]

PMID:
30320663
14.

Sex hormones and their influence on chronic kidney disease.

Valdivielso JM, Jacobs-Cachá C, Soler MJ.

Curr Opin Nephrol Hypertens. 2018 Oct 12. doi: 10.1097/MNH.0000000000000463. [Epub ahead of print]

PMID:
30320621
15.

Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy.

Aoun F, Albisinni S, van Velthoven R.

Curr Opin Urol. 2018 Oct 12. doi: 10.1097/MOU.0000000000000560. [Epub ahead of print]

PMID:
30320610
16.

Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience.

Facchini G, Cavaliere C, D'Aniello C, Iovane G, Rossetti S.

Anticancer Drugs. 2018 Oct 12. doi: 10.1097/CAD.0000000000000703. [Epub ahead of print]

PMID:
30320608
17.

Let there be oxygen and T cells.

Walker PR.

J Clin Invest. 2018 Oct 15. pii: 124305. doi: 10.1172/JCI124305. [Epub ahead of print]

18.

Anticancer and antibacterial potential of Rhus punjabensis and CuO nanoparticles.

Naz S, Tabassum S, Freitas Fernandes N, Mujahid M, Zia M, Carcache de Blanco EJ.

Nat Prod Res. 2018 Oct 15:1-6. doi: 10.1080/14786419.2018.1495633. [Epub ahead of print]

PMID:
30320505
19.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2. [Epub ahead of print] Review.

PMID:
30320443
20.

Inhibitory effects of Schisandrin B on human prostate cancer cells.

Nasser MI, Han T, Adlat S, Tian Y, Jiang N.

Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6791. [Epub ahead of print]

PMID:
30320364

Supplemental Content

Loading ...
Support Center